Novartis cholesterol drug failure raises doubts in race
By The BriefBrief
Novartis’ failure in a cholesterol drug effort has cast doubt on the multibillion-dollar race to lower Lp(a) levels and reduce heart attacks and strokes. The setback increases pressure on Amgen and Eli Lilly as they compete to translate Lp(a) reduction into fewer cardiovascular events.
WHO:Novartis
WHAT:Novartis’ cholesterol drug effort failed, casting doubt on the Lp(a)-lowering race.
WHEN:Reported Sep 8, 2026 at 1:00 AM ET
WHERE:Location not specified
WHY:Cause not yet established.
Reporting from 2 identified publishers across this event arc.
